Related Experiment Video
Updated: Aug 6, 2026
05:58
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
MitoQ Ameliorates Diabetic Cardiomyopathy by Inhibiting the mtROS-TXNIP-NLRP3 Pathway
Shaohuan Qian1, Junjie Leng1, Zhuoya Yao1
1Department of Cardiovascular Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu City 233000, Anhui, China, bbmc.edu.cn.
Mediators of Inflammation
|July 21, 2026
Summary
Mitoquinone mesylate (MitoQ) effectively treats diabetic cardiomyopathy by reducing mitochondrial reactive oxygen species (mtROS) and inhibiting the TXNIP/NLRP3 inflammasome pathway. This targeted approach offers a promising therapeutic strategy for diabetic myocardial injury.
Area of Science:
- Cardiovascular Research
- Mitochondrial Biology
- Diabetic Complications
Background:
- Diabetic cardiomyopathy (DCM) is a significant complication of diabetes, characterized by cardiac dysfunction and structural changes.
- Mitochondrial dysfunction, particularly increased mitochondrial reactive oxygen species (mtROS) production, plays a crucial role in DCM pathogenesis.
- The thioredoxin-interacting protein (TXNIP)/NOD-like receptor protein 3 (NLRP3) inflammasome pathway is implicated in diabetic myocardial injury.
Purpose of the Study:
- To investigate the therapeutic potential of mitoquinone mesylate (MitoQ) in treating diabetic cardiomyopathy (DCM).
- To elucidate the mechanism by which MitoQ acts, specifically its effect on the mitochondrial reactive oxygen species (mtROS)/TXNIP/NLRP3 pathway.
Main Methods:
- Established in vivo (high-fat diet/streptozotocin) and in vitro (high glucose in AC16 cardiomyocytes) models of DCM.
- Utilized immunohistochemistry, western blotting, and mtROS fluorescence staining to assess molecular changes and oxidative stress.
- Employed co-immunoprecipitation (Co-IP) to analyze protein interactions and inflammasome activation.
Main Results:
- Diabetic mice and high-glucose-stimulated cardiomyocytes exhibited increased oxidative stress, mtROS accumulation, TXNIP/NLRP3 inflammasome activation, fibrosis, and impaired cardiac function.
- MitoQ treatment significantly reduced mtROS production, restored mitochondrial membrane potential, inhibited TXNIP-NLRP3 interaction, and suppressed inflammasome activation.
- TXNIP knockdown enhanced MitoQ's protective effects, confirming the critical role of the mtROS/TXNIP/NLRP3 axis in DCM.
Conclusions:
- MitoQ effectively attenuates diabetic myocardial injury by inhibiting mtROS accumulation and suppressing the TXNIP/NLRP3 inflammasome pathway.
- Targeting the mtROS/TXNIP/NLRP3 signaling pathway represents a promising therapeutic strategy for managing diabetic cardiomyopathy.
